Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
15
08
2021
revised:
09
11
2021
accepted:
28
12
2021
pubmed:
5
1
2022
medline:
16
4
2022
entrez:
4
1
2022
Statut:
ppublish
Résumé
CD137 molecule is expressed by activated lymphocytes, and in patients with cancer identifies the tumor-reactive T cells. In solid tumors, high levels of circulating CD137+ T cells are associated with the clinical response and the disease-free status. Here, we examined the role of the CD137+ T cells in the improvement of patients' selection for immunotherapy treatment. Peripheral blood mononuclear cells derived from 109 patients with metastatic cancer (66 patients for the identification cohort and 43 for the validation cohort) were analyzed for the expression of CD3, CD4, CD8, CD137, and PD1 molecules before the beginning of anti-PD1 therapy. Twenty healthy donors were used as control. The soluble form of CD137 (sCD137) was also analyzed. The CD137+ T cell subsets and the sCD137 were correlated with the clinicopathologic characteristics. The distribution of CD137+ T cells was also examined in different tumor settings. The percentage of CD137+ T cells was higher in healthy donors and in those patients with a better clinical status (performance status = 0-1, n°metastasis≤2) and these high levels were ascribed to the CD8+CD137+ T cell population. The high frequency of CD137+ and CD8+CD137+ T cells resulted as a prognostic factor of overall survival (OS) and progression-free survival (PFS), respectively, and were confirmed in the validation cohort. High levels of CD3+CD137+PD1+ lymphocytes were associated with a low number of metastasis and longer survival. Instead, the high concentration of the immunosuppressive sCD137 in the serum is associated with a lower PFS and OS. In tumor bed, patients with a complete response showed a high percentage of CD137+ and CD8+ T cells. We propose the CD137+ T subset as an immune biomarker to define the wellness status of the immune system for successful anticancer immunotherapy.
Identifiants
pubmed: 34980602
pii: 1078-0432.CCR-21-2918
doi: 10.1158/1078-0432.CCR-21-2918
pmc: PMC9377756
doi:
Substances chimiques
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1027-1037Subventions
Organisme : Sapienza University of Rome
ID : RM120172B803DB14
Organisme : AIRC
ID : IG 2015 no.17432
Organisme : Department of Experimental Medicine, Sapienza University of Rome
Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
J Leukoc Biol. 2020 May;107(5):731-738
pubmed: 32052477
Cell Mol Immunol. 2011 Jul;8(4):281-4
pubmed: 21217771
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Int J Cancer. 2014 Dec 15;135(12):2857-67
pubmed: 24789574
Cancer Discov. 2012 Jul;2(7):608-23
pubmed: 22719018
Front Oncol. 2021 Mar 25;11:558248
pubmed: 33842304
Mol Cells. 2011 Feb;31(2):141-9
pubmed: 21347708
J Leukoc Biol. 2011 Jan;89(1):21-9
pubmed: 20643812
EBioMedicine. 2020 Dec;62:103098
pubmed: 33166793
Eur J Immunol. 2008 Apr;38(4):1024-32
pubmed: 18395851
Hepatology. 2020 Mar;71(3):955-971
pubmed: 31353502
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Nat Commun. 2017 Sep 19;8(1):592
pubmed: 28928380
J Immunol. 2002 May 1;168(9):4262-7
pubmed: 11970964
J Exp Med. 1998 Jun 1;187(11):1849-62
pubmed: 9607925
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Blood. 2009 Oct 15;114(16):3431-8
pubmed: 19641184
Nat Rev Immunol. 2017 Jan;17(1):21-29
pubmed: 27916977
J Immunol Methods. 2008 Nov 30;339(1):23-37
pubmed: 18760281
Int Rev Immunol. 2015 Mar;34(2):123-33
pubmed: 25901857
J Exp Med. 2018 Apr 2;215(4):1091-1100
pubmed: 29511066
Front Immunol. 2021 Jun 24;12:675146
pubmed: 34248957
Blood. 2010 Mar 11;115(10):1941-8
pubmed: 20068221
Cancer Immunol Res. 2018 Jan;6(1):69-78
pubmed: 29133290
J Immunol. 2001 Aug 1;167(3):1313-24
pubmed: 11466348
Front Immunol. 2017 Oct 10;8:1211
pubmed: 29067023
Cancer Immunol Res. 2018 Jun;6(6):711-722
pubmed: 29700053
Cancers (Basel). 2020 Sep 14;12(9):
pubmed: 32937860
Cancers (Basel). 2019 Jul 26;11(8):
pubmed: 31357439
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Curr Opin Organ Transplant. 2008 Aug;13(4):366-72
pubmed: 18685331
Am J Clin Pathol. 2001 Apr;115(4):543-9
pubmed: 11293902
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
JAMA Oncol. 2020 Oct 1;6(10):1606-1610
pubmed: 32469396
BMB Rep. 2014 Mar;47(3):122-9
pubmed: 24499671